Health Experts Raise Alarm Over GLP-1 Weight Loss Drugs Triggering Eating Disorders

May 1, 2026

Health experts are raising alarms as GLP-1 weight loss drugs like Wegovy and Ozempic are increasingly prescribed without adequate mental health screening. While these medications show promise in treating binge eating disorder, their profound appetite-suppressing effects pose severe risks for individuals with histories of restrictive eating. Experts warn that GLP-1 use can trigger or exacerbate life-threatening restrictive disorders like anorexia nervosa, yet manufacturers and major medical associations have not established consistent screening guidelines.

GLP-1 medication mechanisms

▪GLP-1 receptor agonists have been linked to improved cardiovascular outcomes, a reduced risk of kidney disease, and a reduced desire to drink alcohol.
▪GLP-1 receptor agonists mimic a naturally occurring hormone called glucagon-like peptide-1, which regulates blood sugar, slows digestion, and signals fullness to the brain.

Eating disorder types

▪Anorexia nervosa is characterized by an intense fear of gaining weight, a distorted body image, and extreme restriction of food intake leading to dangerously low body weight.
▪Bulimia nervosa involves recurrent episodes of binge eating followed by compensatory behaviors, such as purging, fasting, or excessive exercise, to prevent weight gain.
▪Binge eating disorder involves recurrent episodes of consuming large amounts of food with a sense of loss of control at least once a week over a three-month period.
▪Avoidant/Restrictive Food Intake Disorder involves a severe pattern of avoiding certain foods or selective eating that results in failure to meet nutritional needs without body shape concerns.

Binge eating disorder prevalence

▪Binge eating disorder is the most common eating disorder in the United States, affecting roughly 3% of the population at some point.
▪A systematic review of over 94,000 adults seeking obesity treatment found that 14% had binge eating disorder on clinical interview and up to 26% reported moderate-to-severe binge eating.

Clinical screening gaps

▪The manufacturers of Wegovy, Ozempic, and Zepbound do not mention the risks to individuals with pre-existing eating disorders in their accompanying product literature.
▪The American Academy of Family Physicians has not adopted consistent guidelines or generalized recommendations regarding GLP-1 prescribing risks for patients with pre-existing eating disorders.
▪A joint advisory from major medical organizations states that restrictive eating disorder is a general contraindication to GLP-1 use, requiring specialist referral before prescribing.

Neurological appetite changes

▪GLP-1 receptors exist throughout the brain, including the hypothalamus, which controls appetite, and the mesolimbic reward system, which is involved in addiction and compulsive behavior.
▪GLP-1 medications change how the brain processes hunger, fullness, and food reward, leading to reduced food cravings, less emotional eating, and a quieting of food noise.

Restrictive eating risks

▪Preliminary evidence suggests that the use of GLP-1 drugs could exacerbate and lead to new diagnoses of restrictive eating disorders, including anorexia nervosa.
▪GLP-1 medications can cause profound appetite suppression that can reinforce dangerous food restriction patterns and reduce food intake to medically dangerous levels in patients with restrictive eating.
▪Nutrient deficiencies, electrolyte abnormalities, orthostatic hypotension, osteopenia, sarcopenia, and thinning hair have been observed in users of GLP-1 agents.